After Abbott, India Market Bug Bites Mylan Too As It Sets Sights On Stage-wise Product Rollout
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - The potential of the Indian pharmaceutical market to double from the present $8 billion to $15 billion in the next five years led Abbott last week to strike the most richly valued deal for Piramal Healthcare's generic drug businesses, but the action for a share of the Indian market is set to accelerate further as Mylan - the third largest generic company in the world and the largest in the U.S. with sales exceeding $5 billion - is preparing to enter the Indian formulations market
You may also be interested in...
Mylan Weighs "Big Bang Or Phased" Products Rollout In India; Significant Workforce Additions Planned
MUMBAI - On a trip to India, Mylan Inc. CEO and Chairman Robert Coury praised the "voluminous contributions" of Indian arm Matrix Laboratories Ltd. in Mylan's global-scale vertical integration drive, but also announced that the company would rebrand Matrix as Mylan as it moves forward with launching Mylan products in India
Mylan Weighs "Big Bang Or Phased" Products Rollout In India; Significant Workforce Additions Planned
MUMBAI - On a trip to India, Mylan Inc. CEO and Chairman Robert Coury praised the "voluminous contributions" of Indian arm Matrix Laboratories Ltd. in Mylan's global-scale vertical integration drive, but also announced that the company would rebrand Matrix as Mylan as it moves forward with launching Mylan products in India
Mylan Weighs "Big Bang" Or "Phased" Products Rollout In India; Significant Workforce Additions Planned
The global generics firm will rebrand Matrix, its Indian arm, as "Mylan," as it anticipates launching its prescription products in India under the Mylan label.